A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults
This descriptive study will evaluate the safety and immunogenicity of 5 different formulations of the WRAIR dengue vaccine compared to a placebo.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
|Official Title:||Observer-Blind, Single Center, Controlled Study of 2 Doses of Various Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6-Mth Schedule, to Healthy Adults|
- Occurrence of any, and grade 3 solicited adverse events (AEs) within 21 days follow-up after dose 1 of study vaccine and N antibody (GMT) to dengue vaccine serotypes 1, 2, 3 and 4, 30 days after the last study vaccine dose.
- "Safety endpoints
- Occurrence of any, and grade 3 solicited adverse events (AEs) within 21 days follow-up after dose 2 of study vaccine;
- Occurrence of each type of any and grade 3 solicited AE within the 21-day solicited follow-up period after each dose;
- Occurrence of unsolicited AEs within 31 days (days 0-30) after any study vaccine dose;
- Occurrence of serious adverse events (SAEs) throughout the entire study period;
- Occurrence of alert values for safety laboratory determinations within 31 days after each vaccine dose.
- Immunogenicity endpoints
- N antibody ≥ 1:10 to each dengue vaccine serotype, 30 days after each dose;
- Tetravalent N antibody, 30 days after each dose;
- Occurrence of measurable dengue viremia at specified time points following each vaccine dose.
- Additional endpoints
- Selected cell-mediated immunity readouts after each dose
- Occurrence of disseminated infections among blood fed mosquitoes after dose 1
|Study Start Date:||April 2006|
|Primary Completion Date:||June 2007 (Final data collection date for primary outcome measure)|
Biological: Live attenuated tetravalent dengue vaccine
Subjects will be randomized into one of 6 groups. One group will receive a placebo vaccine and the others will receive one of 5 different dengue vaccine formations. Each subject will receive two doses six months apart. Study subjects who elect to participate in a mosquito transmissibility component of the study will undergo mosquito feedings during each of the two assigned follow-up visits after vaccine dose 1. All subjects will have 11 venipunctures during 11 visits (i.e., screening plus 10 study visits) over a period of nine months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00239577
|United States, Maryland|
|GSK Investigational Site|
|Silver Spring, Maryland, United States, 20910|
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|